FDA verdict for Cubist antibiotic tedizolid expected in June; priority granted
This article was originally published in Scrip
Executive Summary
Shares of Cubist Pharmaceuticals nudged up 1.6%, or $1.09, in morning trading on 30 December on the news the FDA granted a priority review of the firm's new drug application (NDA) for its experimental antibiotic tedizolid phosphate (TR-701).